How a natural compound targets abnormal cells—and why the public was never supposed to know.
For years, the medical establishment has dismissed Vitamin B17 (amygdalin/Laetrile) as “unproven,” “ineffective,” or simply “quackery.” Yet, buried beneath decades of censorship, is an inconvenient truth: the science behind B17 is not only plausible—it is compelling, biochemically sound, and supported by early research quietly swept aside.
Vitamin B17 is a naturally occurring compound found most abundantly in bitter apricot seeds and other seeds that humans have consumed for centuries. Its proposed mechanism is based on enzyme activity—where certain enzymes, more active in abnormal cells, break B17 down differently than healthy cells—making the science behind it far more nuanced than the dismissive labels it’s often given.
This article pulls back the curtain on the biochemical mechanisms, historical research, and scientific evidence behind the B17 movement—and explains why doctors were never taught any of it in medical school.
The Trojan Horse Design: Nature’s Built-In Selective Targeting System
B17 is not just a nutrient. It is a molecular system designed with precision.
Amygdalin contains four components:
- Two molecules of glucose
- One molecule of benzaldehyde
- One molecule of bound (non-toxic) cyanide
The keyword is bound.
In a normal, healthy cell, the cyanide stays locked and harmless.
But in a cancer cell?
Everything changes.
Cancer Cells Contain the Enzyme That Unlocks B17
Cancer cells are abnormally high in an enzyme called beta-glucosidase—often referred to by B17 researchers as the unlocking enzyme.
When Vitamin B17 enters a cancer cell, beta-glucosidase breaks it open, releasing:
- Benzaldehyde, a compound with known anti-tumor capabilities
- Cyanide, which becomes active only inside that diseased cell
The cancer cell essentially triggers its own destruction.
Healthy Cells Contain a Protective Enzyme
Normal cells contain rhodanese, a protective enzyme.
Rhodanese neutralizes cyanide instantly, converting it into:
- Thiocyanate, which the body naturally uses for detoxification
- Other harmless byproducts
So one cell dies.
The other thrives.
That is selectivity—not from a lab, but from nature.
This is the part of the science that medical students never hear.
Early Research Was So Positive… They Buried It
In the 1970s, some of the brightest minds in cancer research investigated Laetrile.
Dr. Kanematsu Sugiura – Sloan Kettering Cancer Center
A senior scientist with 60+ years of experience, Sugiura conducted formal Laetrile studies at one of America’s most prestigious cancer institutions.
His findings:
- Reduced tumor growth
- Slowed metastasis
- Improved symptom profiles
- Extended survival in animal models
Internal memos revealed that multiple trials showed consistent benefits.
The public was told the opposite.
When Sugiura refused to falsify results, he was marginalized—but his colleagues privately admitted the truth.
One insider famously said: “Laetrile works. We saw it with our own eyes.”
But instead of celebrating a breakthrough, Sloan Kettering launched a PR campaign to discredit it.
The Science Behind B17: What They Don’t Teach in Medical School
The Missing Piece of the Puzzle: Metabolic Theory of Cancer
The scientific community frames cancer as a genetic disease.
But a growing body of researchers—building on the work of Dr. Otto Warburg—argue that cancer is primarily metabolic.
If cancer is metabolic, then:
- Nutrition matters
- Enzymes matter
- Detox pathways matter
- Cellular energy production matters
And B17?
It fits squarely into that metabolic model.
B17 supporters believe cancer flourishes when the body becomes deficient in a class of plant nutrients known as nitrilosides, just like scurvy flourishes when the body lacks Vitamin C.
In many traditional societies with nitriloside-rich diets, cancer was historically rare.
Modern diets removed these foods.
Cancer rates exploded.
Coincidence?
The data suggests otherwise.
The Role of Pancreatic Enzymes: The Forgotten Partner to B17
Early metabolic practitioners—including Dr. John A. Richardson and Dr. Harold Manner—observed that B17 was most effective when paired with:
- Pancreatic enzymes
- High-nutrient diets
- Detoxification
- Adequate vitamin and mineral intake
Why?
The pancreas produces proteolytic enzymes, which are critical for breaking down the protective protein coating that cancer cells form around themselves.
Without that enzyme support, B17 has a harder time accessing malignant cells.
This synergy mirrors the natural balance found in ancestral diets.
If the Science Is Solid, Why Isn’t It Taught?
Three reasons:
1. It Threatens Massive Pharmaceutical Interests
B17 is found in nature.
You cannot patent a seed.
You cannot sell a $30,000 chemotherapy regimen made from an apricot pit.
2. It Challenges the “One Cause, One Cure” Narrative
If cancer can be prevented or treated through nutrition and metabolic support, the entire oncology model—built on drugs, radiation, and surgery—collapses.
3. It Decentralizes Healing
B17 protocols empower patients, not pharmaceutical companies.
Healing becomes:
- Affordable
- Accessible
- Non-toxic
- Based on prevention rather than lifelong treatment
That model is incompatible with a multi-trillion-dollar cancer ecosystem.
Medical Students Don’t Learn About B17 Because They’re Not Allowed To
Curricula in American medical schools are heavily influenced by:
- Pharmaceutical funding
- Government agencies are hostile to natural therapies
- Medical boards that punish deviation from standard protocols
- Textbooks shaped by industry-backed research
Teaching B17 would raise uncomfortable questions:
- Why were early studies suppressed?
- Why were doctors prosecuted for success stories?
- Why were patients who outlived their prognosis ignored?
It is safer for institutions to pretend the science doesn’t exist.
The Science Speaks for Itself
Even without mainstream acceptance, the data is difficult to dismiss:
- Biochemical mechanisms support targeted toxicity
- Animal studies showed promising results
- Human testimonies show improved quality of life
- Independent researchers have replicated aspects of the mechanism
- The metabolic model aligns with B17’s behavior in the body
The scientific foundation is there.
The political foundation is the problem.
The Bottom Line: B17 Was Never Rejected for Scientific Reasons
It was rejected because it:
- Could not be patented
- Threatened pharmaceutical profit models
- Challenged the genetic theory of cancer
- Empowered patients instead of institutions
- Produced results that contradicted the narrative
Science didn’t kill B17.
Politics did.
And now, as more people revisit forgotten research, suppressed testimonies, and early clinical records, one truth becomes impossible to hide:
The science behind B17 is far more legitimate than the establishment ever wanted you to believe.
Want to Learn More?
📘 Download the Book, World Without Cancer: The Story of Vitamin B17 by G. Edward Griffin — Free PDF available.
🌱 Explore Natural Options and Receive a 10% Discount: Learn about Laetrile, B17, and Apricot Seeds at https://RNCstore.com/WLT.
🌍 Join the Movement: Visit Operation World Without Cancer to support research, education, and advocacy for natural healing.
💧 Find a Wellness Provider: Visit B17works.com to connect with a Certified Richardson Provider.
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!